Literature DB >> 7525824

Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease.

P Cohen1, D M Peehl, H C Graves, R G Rosenfeld.   

Abstract

Prostate specific antigen (PSA) is an insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) protease found in seminal plasma and produced by prostatic epithelial cells (PC-E) in vivo. We examined the effects of PSA-proteolysis of IGFBP-3 on the affinity of IGFBP-3 fragments for IGFs and on the mitogenic action of IGFs on PC-E. Recombinant human IGFBP-3 was cleaved by PSA, then incubated with 125I-IGF-I or -II in the presence of varying concentrations of unlabelled peptides, and then cross-linking electrophoresis and densitometric analysis were performed. While the affinity of IGF-II for the PSA-generated IGFBP-3 fragments fell slightly compared to intact IGFBP-3, the affinity of the PSA-generated IGFBP-3 fragments for IGF-I fell by ten fold. The addition of IGF-I or -II to PC-E in serum-free culture conditions resulted in a two-fold stimulation of cell number compared to control. The presence of IGFBP-3 in the media blocked the IGF-induced stimulation, but had no independent effect in the absence of IGFs. When PSA was added to PC-E cultures to which both IGF-I or -II and IGFBP-3 were added, the inhibitory effects of IGFBP-3 on IGF mitogenesis were reversed. We conclude that PSA decreases the affinity of IGFBP-3 for IGF and can potentiate IGF action in the presence of inhibitory IGFBP-3. This phenomenon may contribute to normal and malignant prostate growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525824     DOI: 10.1677/joe.0.1420407

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  48 in total

Review 1.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

Review 2.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

Review 3.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 4.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 5.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 6.  General aspects of insulin-like growth factor binding proteins.

Authors:  K Chan; E M Spencer
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 7.  Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases.

Authors:  S E Nunn; T B Gibson; R Rajah; P Cohen
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

8.  Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.

Authors:  Jeremy G Stone; Raj K Rolston; Masumi Ueda; Hyoung-Gon Lee; Sandy L Richardson; Rudy J Castellani; George Perry; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-10-20

Review 9.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 10.  Molecular mechanisms of metastasis in prostate cancer.

Authors:  Noel W Clarke; Claire A Hart; Mick D Brown
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.